# Jon and Mindy Gray bet $55M on AI to catch cancer before it starts > Source: > Published: 2026-06-30 14:38:24+00:00 *A new institute at Penn’s Basser Center will use artificial intelligence and biomarkers to intercept hereditary cancers at their earliest stages, before they become disease.* The idea behind the gift is unusual enough to need its own word. Most cancer philanthropy funds treatment, the long campaign that begins once a tumour has announced itself. Jon and Mindy Gray are funding something earlier, a discipline its champions call interception, which aims to stop hereditary cancers before they ever become disease. Their $55 million has created the Basser Cancer Interception Institute at the University of Pennsylvania, and artificial intelligence sits close to the centre of how it intends to work. The institute grows out of the Grays’ long involvement with BRCA research. Mindy Gray’s sister, Faith Basser, died of ovarian cancer at 44, and the couple founded Penn’s Basser Center for BRCA in her memory, beginning with a $25 million gift and building, over the years, to commitments now well past $250 million across their philanthropy. The new institute extends that work from understanding the BRCA mutations that drive inherited cancer risk toward catching the resulting cancers at the first possible moment. Jon Gray is not a figure usually found in oncology headlines. He is the president and chief operating officer of Blackstone, the asset-management giant, and one of the more prominent names in American finance. The cancer work is personal rather than professional, a parallel life built around a single family loss, and it has made the Grays among the more significant private funders of hereditary-cancer science in the United States. What makes the new institute a technology story is the method. The Basser team plans to pioneer approaches ranging from drugs and immune-based therapies that intercept BRCA-related cancers to new ways of detecting cancerous cells using biomarkers and artificial intelligence. The premise is that the signals of a cancer beginning to form, faint patterns in blood, tissue, and molecular data, are exactly the kind of needle-in-a-haystack problem that machine learning is suited to, where a model can spot a signature a human eye would miss. Interception, if it works, changes the economics and the experience of cancer in a way treatment cannot. Catching a malignancy in its earliest molecular stirrings, or stopping it before it forms at all, is both cheaper and vastly less brutal than fighting an established tumour. For people who carry BRCA mutations and live with the knowledge that their lifetime risk is elevated, the prospect of early interception is a different relationship with that risk entirely. The bet rides a broader wave of AI moving into the biology of cancer. Machine-learning systems are being trained to read medical images at expert-level accuracy, to surface the molecular drivers of tumours, and to compress the slow work of [drug discovery and oncology trials](https://thenextweb.com/news/akeso-ivonescimab-lung-cancer-asco-china-biotech). The Gray gift points that capability at the front of the timeline, at detection and prevention rather than the later stages where most AI cancer tools have so far been aimed. It also lands amid an enormous influx of capital and computing power into AI for science generally, as foundation-model techniques are turned on problems in chemistry, genomics, and medicine. Much of that money chases commercial drug pipelines; a philanthropic gift aimed squarely at interception is a quieter and more specific bet, funding the unglamorous early-detection research that markets tend to underwrite less readily than blockbuster therapeutics. The institute is new, and the science of interception is genuinely hard, dependent on finding biomarkers reliable enough to act on without subjecting healthy people to false alarms and unnecessary intervention. The Grays are not promising a cure, but they are funding a wager that the earliest signs of cancer are legible, if the right tools are trained to read them, and that catching the disease at its beginning is worth building an institute around. For a couple who started down this road after losing one person to a cancer caught too late, the logic of getting there earlier needs no further explanation. ## Get the TNW newsletter Get the most important tech news in your inbox each week.